Kurzfassung

A phase I/II multicenter, open-label study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in patients with hepatocellular carcinoma and WNT signaling alterations.
DKN-01 will be administered as a monotherapy and in combination with sorafenib. Sorafenib is a multi-target kinase inhibitor used extensively for treatment of HCC (Keating GM, Target Oncol, 2017). Sorafenib has clinical benefit through inhibition of angiogenesis (Berretta M, Frontiers in Pharmacology, 2016)....A phase I/II multicenter, open-label study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in patients with hepatocellular carcinoma and WNT signaling alterations.
DKN-01 will be administered as a monotherapy and in combination with sorafenib. Sorafenib is a multi-target kinase inhibitor used extensively for treatment of HCC (Keating GM, Target Oncol, 2017).  Sorafenib has clinical benefit through inhibition of angiogenesis (Berretta M, Frontiers in Pharmacology, 2016).  DKK1 has been demonstrate to have pro-angiogenic activity in both breast cancer and liver cancer models (Smadja DM, Arterioscler Thromb Vasc Biol, 2010; Tung Liver International, 2013).  In addition, DKN-01 had anti angiogenic activity in a NSCLC A549 xenograft model (See Investigator’s Brochure).  The combination of DKN-01 and Sorafenib may have additive benefit or synergistic effects when co-administered to HCC patients.» weiterlesen» einklappen